Portage Biotech Inc. (PRTG)
- Previous Close
0.2940 - Open
0.2940 - Bid --
- Ask --
- Day's Range
0.2600 - 0.2950 - 52 Week Range
0.2000 - 3.9500 - Volume
149,381 - Avg. Volume
300,534 - Market Cap (intraday)
5.263M - Beta (5Y Monthly) 95.43
- PE Ratio (TTM)
-- - EPS (TTM)
-8.5200 - Earnings Date Jul 29, 2024 - Aug 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
www.portagebiotech.comRecent News: PRTG
Performance Overview: PRTG
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PRTG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PRTG
Valuation Measures
Market Cap
5.26M
Enterprise Value
196.65k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.13%
Return on Equity (ttm)
-145.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-144.9M
Diluted EPS (ttm)
-8.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.34M
Total Debt/Equity (mrq)
0.88%
Levered Free Cash Flow (ttm)
-8.47M